Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targetingADCthat is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used incancerresearch related to uterine and ovarian sarcomas^[1].

Trastuzumab duocarmazine (SYD985) (0.0001-100 μg/mL, 24 h) 对 HER^2-和 HER²⁺细胞都有杀伤力，与作用于 T-DM1 的 IC₅₀值为 0.096 μg/mL 相比，对 HER2/NEU³⁺细胞系的杀伤力要高出 7 倍，IC₅₀值为 0.013 μg/mL。更重要的是，在 HER2/NEU¹⁺细胞中，它的杀伤力是 T-DM1 的 54 倍^[1]。

Trastuzumab duocarmazine (SYD985) (3 mg/kg or 10 mg/kg, i.v., once) 均可以显著抑制肿瘤的生长，延长小鼠的生存周期，具有有效的体内抗肿瘤活性^[1]。

1642152-40-6

Please store the product under the recommended conditions in the Certificate of Analysis.